Other
Noncontrolling interests in subsidiaries
Royalty Pharma Noncontrolling interests in subsidiaries decreased by 5.9% to $3.05B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.7%, from $3.10B to $3.05B. Over 5 years (FY 2020 to FY 2025), Noncontrolling interests in subsidiaries shows a downward trend with a -8.6% CAGR.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryOther
SignalContext dependent
VolatilityStable
First reportedQ4 2016
Last reportedQ1 2026
How to read this metric
Changes reflect the acquisition or divestiture of minority stakes in subsidiaries or the relative profitability of those specific entities.
Detailed definition
This represents the portion of equity in a subsidiary that is not attributable, directly or indirectly, to the parent co...
Peer comparison
Common in companies with complex organizational structures and joint ventures.
Metric ID:
other_minority_interestHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.67B | $4.59B | $4.47B | $4.36B | $4.38B | $4.26B | $3.90B | $3.87B | $3.53B | $3.45B | $3.56B | $3.36B | $3.28B | $3.39B | $3.40B | $3.10B | $3.16B | $3.21B | $3.24B | $3.05B |
| QoQ Change | — | -1.7% | -2.6% | -2.4% | +0.4% | -2.7% | -8.6% | -0.7% | -8.7% | -2.4% | +3.2% | -5.4% | -2.6% | +3.5% | +0.2% | -8.7% | +1.8% | +1.6% | +1.0% | -5.9% |
| YoY Change | — | — | — | — | -6.2% | -7.2% | -12.9% | -11.4% | -19.4% | -19.2% | -8.7% | -13.0% | -7.3% | -1.7% | -4.6% | -7.8% | -3.7% | -5.4% | -4.6% | -1.7% |
Range$3.05B – $4.67B
CAGR-8.6%
Avg YoY Growth-8.4%
Median YoY Growth-7.2%
Noncontrolling interests in subsidiaries at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's noncontrolling interests in subsidiaries?
- Royalty Pharma (RPRX) reported noncontrolling interests in subsidiaries of $3.05B in Q1 2026.
- How has Royalty Pharma's noncontrolling interests in subsidiaries changed year-over-year?
- Royalty Pharma's noncontrolling interests in subsidiaries decreased by 1.7% year-over-year, from $3.10B to $3.05B.
- What is the long-term trend for Royalty Pharma's noncontrolling interests in subsidiaries?
- Over 5 years (2020 to 2025), Royalty Pharma's noncontrolling interests in subsidiaries has grown at a -8.6% compound annual growth rate (CAGR), from $5.08B to $3.24B.
- What does noncontrolling interests in subsidiaries mean?
- The portion of a subsidiary's equity owned by outside investors.